Hemolytic disease of the newborn (also called erythroblastosis fetalis) is a condition in which, the fetal red cell cross the placenta and the mother is immunized with these fetal red cell antigen, the resulting immune response triggers the production of IgG antibodies, often in high titres and with high affinity that are then transferred to the fetus and cause hemolysis of fetal red cells.The conventional treatment measures for neonatal immune hemolytic disease are phototherapy and blood exchange transfusion. Exchange transfusion is however not without risk. Although the mortality rate for exchange transfusion has been reported to be between 0.3-1.2%.High dose intravenous immunoglobulin therapy has been efficaciously and successfully used in the treatment of neonatal immune hemolytic disease which is less invasive than exchange transfusion and without any adverse reaction.